^
Association details:
| Biomarker: | SOX11 expression |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age = 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial
Published date:
11/06/2019
Excerpt:
...131 previously untreated young (≤65 years) pts with MCL….Pts received IR induction (part-A),...17 pts had complex karyotype and 83% had positive SOX-11 expression. Median number of cycles on IR in part A was 7 (1-12). At week 16 on part A, the ORR was 95% (22% CR and 73% PR) and 5% pts had stable disease.
DOI:
https://doi.org/10.1182/blood-2019-126044
Trial ID: